Lantheus Withdraws and Resubmits HSR Filing for $8 Billion Curium Acquisition
Lantheus Holdings has withdrawn its Hart-Scott-Rodino (HSR) Act pre-merger notification with the Federal Trade Commission regarding its proposed acquisition of Curium. The company refiled the filing on September 17 to provide updated information, likely in response to regulatory scrutiny or requests for additional details from the FTC. The $8 billion deal is a significant transaction that could reshape the radiopharmaceutical industry if approved. By withdrawing and resubmitting its HSR filing, Lantheus aims to address any concerns raised by regulators during their review process. The move suggests ongoing regulatory engagement as part of securing clearance for this major acquisition. The re-filing indicates a procedural step in navigating the complex approval landscape required for large-scale mergers within highly regulated sectors like healthcare and pharmaceuticals.
Tickers: $LNTH
Topics: FTC M&A Regulatory Filings